Agenus Posts 48% Q2 Revenue Miss

Agenus (NASDAQ:AGEN), a clinical-stage biotechnology company focused on developing cancer immunotherapies, reported its second quarter 2025 earnings on August 11, 2025. The company's revenue (GAAP) totaled $25.7 million, well below analyst expectations of $49.71 million (GAAP) -- a miss of 48.3% (GAAP). The results reflect a significant shortfall on both top and bottom lines on a GAAP basis. Despite the financial underperformance, the company made material clinical and regulatory advances, most notably securing U.S. Food and Drug Administration agreement to initiate a streamlined Phase 3 trial for its key cancer therapy. Overall, the period featured operational improvements but underwhelming financials. Source: Analyst estimates for the quarter provided by FactSet. Agenus specializes in immuno-oncology, developing therapies that help the body's immune system fight cancer. Its main product candidates are part of a new class of medicines called checkpoint inhibitors, which are designed to disrupt cancer cells' ability to avoid immune detection.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool